Related Experiment Video
Updated: Jan 21, 2026
Large-Animal Model of Donation after Circulatory Death and Normothermic Regional Perfusion for Cardiac Assessment
Published on: May 10, 2022
For Whom the Bell Tolls : Refining Risk Assessment for Sudden Cardiac Death
Ivaylo Tonchev1, David Luria1, David Orenstein1
1Hadassah Medical Center, Heart Institute, Hebrew University in Jerusalem Medical School, Kyriat Hadassah, PO Box 12000, 91120, Jerusalem, Israel.
Insights
Sudden cardiac death (SCD) risk is decreasing due to advanced treatments, but remains high in non-ischemic cardiomyopathy and channelopathy patients. Improved risk stratification and novel therapies are crucial for primary prevention.
Area of Science:
- Cardiology
- Preventive Medicine
- Medical Technology
Background:
- Sudden cardiac death (SCD) is a leading global cause of mortality.
- Medical advancements, including percutaneous interventions and device therapy (implantable cardioverter-defibrillators [ICDs] and cardiac resynchronization therapy with defibrillation [CRTD]), have reduced mortality, particularly in SCD survivors and patients with ischemic cardiomyopathy and reduced left ventricular function.
- However, patients with non-ischemic cardiomyopathies, mildly reduced left ventricular function, and channelopathies face an elevated risk of SCD, necessitating improved identification and intervention strategies.
Purpose of the Study:
- To provide a comprehensive overview of sudden cardiac death (SCD) etiologies.
- To summarize current knowledge on risk stratification and primary prevention strategies for SCD.
- To identify evidence gaps and discuss future directions for screening and treating patients at risk for SCD.
Main Methods:
- Literature review of current knowledge on sudden cardiac death (SCD).
- Analysis of recent findings on risk stratification and therapeutic interventions.
- Discussion of novel approaches and emerging therapies for SCD prevention.
Main Results:
- The incidence of SCD has declined due to improved pharmacological treatments and ICD implantation in specific patient groups.
- The efficacy of ICDs in non-ischemic cardiomyopathy patients is under scrutiny following new trial data.
- Catheter ablation is an emerging strategy for preventing SCD in patients with specific ventricular arrhythmias.
Conclusions:
- Despite treatment advancements, SCD remains a significant health burden.
- Implantable cardioverter-defibrillators (ICDs) are standard for ischemic cardiomyopathy, but better risk stratification is needed for non-ischemic cardiomyopathies and channelopathies.
- Further research is required to establish the role of catheter ablation in SCD prevention.
Abstract:
Sudden cardiac death is one of the most important causes of death worldwide. Advancements in medical treatment, percutaneous interventions, and device therapy (ICD and CRTD) showed consistent reduction in mortality, mainly in survivors of SCD and in patients with ischemic cardiomyopathy and depressed left ventricular function. Patients with non-ischemic cardiomyopathies, mildly reduced LV function, and channelopathies have increased risk for SCD. Identifying the subgroup of these patients before they experience life-threatening or fatal events is essential to further improve outcomes. In this review, we aimed to summarize the current knowledge for risk stratification and primary prevention, to describe the gaps in evidence, and to discuss future directions for screening and treating patients at risk for SCD. PURPOSE OF REVIEW: The purpose of this review is to provide a comprehensive description of the etiologies of sudden cardiac death, risk stratification strategies, and to describe the current medical and interventional therapies. We aimed to discuss the current gaps in our knowledge of primary prevention of SCD and to review novel approaches and interventions. RECENT FINDINGS: The incidence of SCD has decreased in the last two decades due to improved pharmacological treatment and ICD implantation in SCD survivors and in patients with reduced left ventricular function and ischemic cardiomyopathy. The efficacy of ICD in patients with non-ischemic cardiomyopathy is challenged by new findings from the DANISH trial. Catheter ablation is new emerging strategy to prevent SCD in patients with scar relater or PVC-triggered ventricular arrhythmias. Despite the new treatments, SCD is still a major burden. ICD remains the cornerstone for patients with ischemic cardiomyopathy, whereas appropriate risk stratification of the patients with non-ischemic cardiomyopathy and channelopathies is needed to further improve outcomes. The future of ablation as the treatment and prevention of SCD remains to be studied.
More Related Videos
19:15Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
Published on: August 25, 2014
08:28Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
Published on: April 5, 2011
Related Concept Videos
01:21The Bell Curve
This pattern applies to many human characteristics beyond intelligence, such as height. For example, if you...
01:17Design Example: Analyzing Capacity Contours for Flood Risk Assessment
01:12Relative Risk
01:30Overview of Cell Death
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...
01:26Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
01:18Autophagic Cell Death
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...